UNICA IRIS Institutional Research Information System

FRAU, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 79.730
NA - Nord America 3.421
AS - Asia 1.473
SA - Sud America 169
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 84.831
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 78.887
US - Stati Uniti d'America 3.383
SG - Singapore 577
CN - Cina 541
UA - Ucraina 256
SE - Svezia 193
BR - Brasile 132
VN - Vietnam 132
FI - Finlandia 93
DE - Germania 86
GB - Regno Unito 74
FR - Francia 62
HK - Hong Kong 54
IN - India 41
KR - Corea 32
BD - Bangladesh 23
CA - Canada 20
RU - Federazione Russa 19
IQ - Iraq 11
NL - Olanda 11
PL - Polonia 11
ZA - Sudafrica 11
AR - Argentina 10
BE - Belgio 9
JP - Giappone 9
MX - Messico 8
TR - Turchia 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
CO - Colombia 6
EU - Europa 6
UZ - Uzbekistan 6
EG - Egitto 5
IR - Iran 5
CL - Cile 4
ID - Indonesia 4
IE - Irlanda 4
KE - Kenya 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
JM - Giamaica 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
SA - Arabia Saudita 3
SV - El Salvador 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
GR - Grecia 2
IL - Israele 2
JO - Giordania 2
KZ - Kazakistan 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
VE - Venezuela 2
AU - Australia 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ES - Italia 1
ET - Etiopia 1
GA - Gabon 1
HR - Croazia 1
KW - Kuwait 1
LU - Lussemburgo 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 84.831
Salva come PNG Salva come JPEG
Città #
Cagliari 77.653
Uta 1.071
Singapore 315
Ashburn 299
Woodbridge 294
Fairfield 287
Chandler 264
San Jose 205
Ann Arbor 143
Jacksonville 140
Nyköping 136
Houston 132
Seattle 124
Boardman 117
Wilmington 117
Dallas 106
Dearborn 102
Cambridge 97
Beijing 95
New York 77
Los Angeles 74
Helsinki 54
Santa Clara 51
Hong Kong 42
Nanjing 40
Shanghai 37
Ho Chi Minh City 35
Lauterbourg 35
Council Bluffs 34
Hefei 32
Boston 31
Seoul 29
Guangzhou 26
Hanoi 25
Milan 24
Buffalo 21
Shenyang 20
The Dalles 20
Redwood City 19
San Diego 18
Dong Ket 16
Jinan 15
Hebei 13
Orem 13
Norwalk 12
Changsha 11
Jiaxing 11
Toronto 11
Mountain View 10
Munich 10
Phoenix 10
Brooklyn 9
Brussels 9
Chicago 9
Frankfurt am Main 9
Nanchang 9
Redondo Beach 9
Hangzhou 8
London 8
Orange 8
Dhaka 7
Düsseldorf 7
São Paulo 7
Tianjin 7
Verona 7
Haiphong 6
Ningbo 6
Oristano 6
Padova 6
Rome 6
Tashkent 6
Warsaw 6
Wuhan 6
Zhengzhou 6
Amsterdam 5
Atlanta 5
Belo Horizonte 5
Modrice 5
Montreal 5
Pune 5
Rio de Janeiro 5
Tokyo 5
Baghdad 4
Campinas 4
Chengdu 4
Chennai 4
Da Nang 4
Gurgaon 4
Indore 4
Kathmandu 4
Kunming 4
La Paz 4
Manchester 4
Mexico City 4
Nuremberg 4
Paris 4
Portsmouth 4
Sassari 4
Stockholm 4
Thái Nguyên 4
Totale 82.852
Salva come PNG Salva come JPEG
Nome #
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.483
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.256
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.174
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.133
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 3.015
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.945
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.855
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.784
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.730
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.703
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.691
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.677
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.633
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.548
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.495
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.423
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.240
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.211
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.172
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.131
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.097
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.095
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.973
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.950
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.889
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.874
Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain 1.754
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.707
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.655
null 1.651
Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age 1.639
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.422
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.294
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.290
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.174
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors 1.104
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra 1.010
null 981
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 967
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs 560
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 333
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 269
Totale 84.987
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.251
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.251
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021589 0 0 0 0 0 0 0 0 0 0 0 589
2021/20223.751 333 284 320 195 175 273 388 277 220 327 355 604
2022/20236.193 733 1.043 648 465 559 542 292 340 399 419 526 227
2023/20245.262 280 370 195 305 541 849 831 336 236 374 392 553
2024/20256.979 1.324 1.426 1.166 910 527 563 607 71 116 77 102 90
2025/20262.925 219 117 258 173 251 225 764 144 171 349 152 102
Totale 84.987